A new Nature Medicine Perspective, “Immune Aging Biomarkers for Clinical Trials,” tackles a question at the heart of HIP’s mission: there’s still no agreed-upon way to measure immune aging. Co-authored by HIP Co-Chief Scientific Officers Shai Shen-Orr and John Tsang, alongside researchers from Stanford, Yale, UConn, University College London, the National Institute on Aging, and others, the paper proposes five criteria for evaluating candidate biomarkers—immune relevance, temporal association, internal validity, predictive value, and responsiveness—and stress-tests them against the real-world XPRIZE Healthspan competition.
Two biomarkers, iAge and IMM-AGE, emerge as the field’s strongest candidates so far. But the authors are clear: getting this right will take longitudinal, multimodal data at population scale—exactly the kind of infrastructure HIP was built to provide.
Read the full paper in Nature Medicine.
Read the full paper in Nature Medicine.
Responses